Mutations in CIC and FUBP1 contribute to human oligodendroglioma

Science

Volumn 333, Issue 6048, 2011, Pages 1453-1455

  Bettegowda, Chetan ^a,b   Agrawal, Nishant ^a,b   Jiao, Yuchen ^a   Sausen, Mark ^a   Wood, Laura D ^b   Hruban, Ralph H ^b   Rodriguez, Fausto J ^b   Cahill, Daniel P ^c   McLendon, Roger ^d   Riggins, Gregory ^a,b   Velculescu, Victor E ^a   Oba Shinjo, Sueli Mieko ^e   Marie, Suely Kazue Nagahashi ^e   Vogelstein, Bert ^a   Bigner, Darell ^d   Yan, Hai ^d   Papadopoulos, Nickolas ^a   Kinzler, Kenneth W ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CAPICUA PROTEIN; FAR UPSTREAM ELEMENT BINDING PROTEIN 1; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

BRAIN; CHROMOSOME; CYTOLOGY; GENE EXPRESSION; GENETIC ANALYSIS; GENETICS; HOMINID; MUTATION; PATHOLOGY; PROTEIN; TUMOR;

ARTICLE; CHROMOSOME 19Q; CHROMOSOME 1P; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; OLIGODENDROGLIOMA; PRIORITY JOURNAL;

BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DNA HELICASES; DNA-BINDING PROTEINS; EXONS; FEMALE; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MUTATION; MUTATION, MISSENSE; OLIGODENDROGLIOMA; RECEPTOR, NOTCH2; REPRESSOR PROTEINS; SEQUENCE ANALYSIS, DNA;

EID: 80052608062     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1210557     Document Type: Article

References (27)

1. S. W. Coons, P. C. Johnson, B. W. Scheithauer, A. J. Yates, D. K. Pearl, Cancer 79, 1381 (1997).
2. J. E.Bromberg, M. J. vandenBent, Oncologist 14, 155 (2009).
3. D. Maintz et al., J. Neuropathol. Exp. Neurol. 56, 1098 (1997).
4. J. S. Smith et al., J. Clin. Oncol. 18, 636 (2000).
5. R. B. Jenkins et al., Cancer Res. 66, 9852 (2006).
6. C. A. Griffin et al., J. Neuropathol. Exp. Neurol. 65, 988 (2006).
7. G. Cairncross, R. Jenkins, Cancer J. 14, 352 (2008).
8. A. G. Knudson Jr., Cancer 35 (suppl.), 1022 (1975).
9. Materials and methods are available as supporting material on Science Online.
10. Y. Jiao et al., Science 331, 1199 (2011).
11. D. W. Parsons et al., Science 321, 1807 (2008).
12. X. S. Puente et al., Nature 475, 101 (2011).
13. H. Yan et al., N. Engl. J. Med. 360, 765 (2009).
14. L. Dang et al., Nature 465, 966 (2010).
15. A. G. Knudson, J. Cancer Res. Clin. Oncol. 122, 135 (1996).
16. S. J. Baker et al., Science 244, 217 (1989).
17. G. Parmigiani et al., Genomics 93, 17 (2009).
18. Catalogue of Somatic Mutations in Cancer, www.sanger.ac.uk/perl/genetics/ CGP/cosmic
19. G. Jiménez, A. Guichet, A. Ephrussi, J. Casanova, Genes Dev. 14, 224 (2000).
20. F. Roch, G. Jiménez, J. Casanova, Development 129, 993 (2002).
21. L. Ajuria et al., Development 138, 915 (2011).
22. S. Astigarraga et al., EMBO J. 26, 668 (2007).
23. C. J. Lee, W. I. Chan, P. J. Scotting, J. Neurooncol. 73, 101 (2005).
24. J. V. Olsen et al., Cell 127, 635 (2006).
25. R. Duncan et al., Genes Dev. 8, 465 (1994).
26. H. H. Hsiao et al., Biochemistry 49, 4620 (2010).
27. M. Kawamura-Saito et al., Hum. Mol. Genet. 15, 2125 (2006).